UK pharmaceutical company GSK is negotiating to acquire oncology biotech Nuvalent for more than $9 billion, potentially finalizing the deal this week. This acquisition would be GSK's largest in over ten years and marks a shift from its recent smaller deals. Nuvalent's key cancer drugs are under FDA review, with potential combined revenues estimated at $823 million by 2029. The deal comes amid a surge in biotech mergers driven by patent expirations and pharma companies seeking to strengthen their drug pipelines.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
